Leaflong Therapeutics Information

Backed by top-tier ventures, Leaflong Therapeutics is an AI-driven clinical platform that helps pharmaceutical companies generate real-world evidence and improve physician engagement at scale. Healthcare is shifting toward more compliant, data-driven, and outcome-based models. Pharmaceutical companies are reallocating significant resources into real-world evidence, patient management, and post-market studies, driven by regulatory requirements and the need for measurable clinical impact. Leaflong addresses this shift by embedding AI directly into clinical workflows. The platform automates patient identification, enables continuous follow-up, and structures clinical data as care happens — transforming routine clinical activity into research-grade datasets without adding burden to clinicians. This allows pharmaceutical companies to: • Accelerate real-world evidence (RWE) generation • Build and maintain stronger clinical and investigator networks • Improve drug utilization and treatment adherence (DOT) • Execute programs in a more compliant and scalable way Leaflong is already deployed across 150+ healthcare institutions, with over 500K patient records structured, 1,500+ clinicians engaged, and 20+ clinical studies supported. The company works with global pharmaceutical partners including AstraZeneca and Sanofi, as well as leading clinical and academic institutions. Our approach creates a compounding data advantage: as clinicians use the platform, high-quality longitudinal data is continuously generated, improving AI performance and increasing value for partners over time. Leaflong is expanding across therapeutic areas and global markets, with a focus on scaling real-world evidence generation.